<DOC>
	<DOCNO>NCT01976572</DOCNO>
	<brief_summary>The primary objective ass effect colestilan pharmacokinetic profile candesartan cilexetil administer time , 1 hour , 3 hour first daily dose colestilan administer dose 5 g three time daily compare administration candesartan cilexetil alone , healthy subject .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Evaluate Effect Colestilan Pharmacokinetics Single Doses Candesartan Cilexetil Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>Able provide write informed consent participate study , read participant information sheet informed consent form ( ICF ) , opportunity discus study Investigator designee . Caucasian male subject age 18 50 year inclusive . A body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive . Healthy subject , free clinically significant illness disease determine medical history , physical examination , electrocardiogram ( ECG ) , vital sign , biochemistry , haematology , coagulation , urinalysis , serology . Male subject , partner , agree use contraception throughout study duration . Male subject must use 1 barrier method contraception spermicide trial , 3 month last dose study drug . Male subject female partner childbearing potential must also agree use additional highly effective method contraception . They must use condom , female partner must use additional method contraception ( cap diaphragm ) , unless subject partner sterilise , case , male subject must use condom spermicide . Subjects clinically significant illness within 4 week start dose administration , determine Investigator base abnormal medical history , physical finding , laboratory value Screening Baseline . Unable swallow colestilan tablet , current and/or history dysphagia . Current history follow gastrointestinal ( GI ) diseases : intestinal obstruction , chronic severe constipation , subileus , ileus , intestinal stenosis , intestinal diverticulosis and/or diverticulitis , colitis , GI ulcer , recent major GI surgery , peritonitis , GI bleeding , gastritis , haemorrhoid , severe GI disease . Current history biliary obstruction , cholestasis , severe hepatic impairment . Current history seizure disorder . Current history Vitamin K deficiency . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . Current recent history ( last 2 year ) abuse addiction ( tobacco , alcohol , drug substance ) , weekly alcohol intake 21 unit , positive alcohol breath test urine drug screen Screening Baseline . One unit equivalent ½ pint ( 280 mL ) beer , 1 measure ( 25 mL ) spirit 1 small glass ( 125 mL ) wine . Treatment drug herbal dietary supplement know inhibitor cytochrome P450 ( CYP ) 3A4 , CYP2C9 Pglycoprotein , 7 day dose inducer CYP3A4 , CYP2C9 , Pglycoprotein 14 day dose . Treatment H2 antagonist and/or proton pump inhibitor , 4 week dose . Subjects history hypotension hyperkalaemia , postural drop systolic blood pressure ≥20 mmHg Screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>CKD Stage V</keyword>
	<keyword>dialysis</keyword>
</DOC>